

ACT your way: A transdiagnostic intervention for multiple disorders in transitional-age youth

Published: 27-01-2022

Last updated: 15-05-2024

The primary aim is to evaluate the effectiveness of ACT your way, by comparing ACT your way to treatment as usual (TAU) in TAY. The secondary aim is to evaluate the cost-effectiveness of ACT your way, by comparing ACT your way to TAU in TAY. The...

Ethical review	Approved WMO
Status	Pending
Health condition type	Psychiatric disorders NEC
Study type	Interventional

Summary

ID

NL-OMON55941

Source

ToetsingOnline

Brief title

ACT your way: a transdiagnostic intervention for TAY

Condition

- Psychiatric disorders NEC

Synonym

Psychopathology, various psychological problems

Research involving

Human

Sponsors and support

Primary sponsor: Universiteit Utrecht

Source(s) of monetary or material Support: ZonMw

Intervention

Keyword: (Cost)effectiveness, Acceptance and commitment therapy, Transdiagnostic intervention, Transitional-age youth

Outcome measures

Primary outcome

The two main primary outcome measures are psychological flexibility (measured with de AFQ-Y) and the number of diagnoses (measured with the SCID-5-Junior, a semi-structured diagnostic interview).

Secondary outcome

Secondary outcomes are the presence of the primary disorder, psychopathology, global functioning, quality of life, individual and societal functioning, emotion regulation, personality problems, autonomy, stress, perfectionism, self-esteem and self-compassion. Other study parameters are demographic information, type and severity of problems, psychopathology of parents, information about previous treatments and life events, treatment expectancy, satisfaction with treatment, therapeutic alliance, information about drop-out, treatment integrity and content of the treatment. Costs are registered in a cost questionnaire.

Study description

Background summary

Transitional-age youth (TAY; aged 15 to 25) has recently been identified as a group in need of special attention in mental health services. Studies show that TAY experience more psychological problems than other age groups. An effective intervention for this specific age group seems warranted. However, there is a lack of interventions specifically developed for this age group. We propose a

transdiagnostic intervention, ACT your way, that can be used for a wide variety of psychological problems and can also be used for chronic and/or recurrent problems in this specific age group.

Study objective

The primary aim is to evaluate the effectiveness of ACT your way, by comparing ACT your way to treatment as usual (TAU) in TAY. The secondary aim is to evaluate the cost-effectiveness of ACT your way, by comparing ACT your way to TAU in TAY. The third aim is to examine for whom ACT you way works best (moderation analyses). The fourth aim is to investigate which factors mediate ACT your way changes (mediation analyses).

Study design

The study is designed as a multi-center, randomized controlled trial. Participants are randomly assigned to the ACT your way or TAU condition. Six multiple informant (adolescent/young adult, parent, therapist) assessments will be conducted: prior to the intervention (pre-treatment), after 3 sessions (mediator 1), after 6 sessions (mediator 2), after 9 sessions (mediator 3), immediately after the intervention (post-treatment) and 6 months after the intervention (6-month follow-up). Assessments will include diagnostic interviews, questionnaires and ratings (i.e., therapist and observational ratings).

Intervention

ACT your way is an intervention based on Acceptance and Commitment Therapy (ACT), that is not directed primarily at symptom reduction but at changing the underlying mechanism of psychopathology, namely psychological inflexibility. ACT you way consists of twelve weekly sessions. Therapists will be trained in using ACT your way.

Study burden and risks

In our opinion, the risks associated with participation can be considered negligible. The burden consists of structured clinical interviews and online questionnaires, which are partly included in the standard diagnostic process of the patient. The intervention that is offered, is independent of participation, patients will receive this intervention whether or not they participate.

Contacts

Public

Universiteit Utrecht

Heidelberglaan 1
Utrecht 3584 CS
NL

Scientific

Universiteit Utrecht

Heidelberglaan 1
Utrecht 3584 CS
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adolescents (12-15 years)

Adolescents (16-17 years)

Adults (18-64 years)

Inclusion criteria

- (1) A primary diagnoses of any disorder (e.g., anxiety disorder, OCD, trauma, depressive disorder, dysthymic disorder, ODD, CD or any combination of these)
- (2) Aged 15 to 25 years
- (3) Referred to one of the participating mental health institutions.

Exclusion criteria

- (1) Insufficient knowledge of the Dutch language
- (2) Acute suicide risk
- (3) Drug abuse
- (4) Absence of TAY or parental permission (for participants younger than 16)
- (5) Estimated IQ below 80
- (6) Unstable medication (i.e. the medication should be set before the start of

the intervention and should remain stable)

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-01-2022
Enrollment:	144
Type:	Anticipated

Ethics review

Approved WMO	
Date:	27-01-2022
Application type:	First submission
Review commission:	METC NedMec
Approved WMO	
Date:	04-05-2022
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	28-12-2022
Application type:	Amendment
Review commission:	METC NedMec

Approved WMO	
Date:	05-05-2023
Application type:	Amendment
Review commission:	METC NedMec
Approved WMO	
Date:	02-11-2023
Application type:	Amendment
Review commission:	METC NedMec

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 23521
Source: NTR
Title:

In other registers

Register	ID
CCMO	NL78679.041.21
Other	NL9642
OMON	NL-OMON23521